Analysis of feasibility of myeloablative therapy and autologous peripheral stem cell (PBSC) transplantation in the elderly: An interim report

Bone Marrow Transplantation

Volumn 23, Issue 12, 1999, Pages 1273-1278

  Mazza, P ^a,d   Palazzo, G ^a   Amurri, B ^a   Cervellera, M ^a   Manna, N ^a   Fellini, G ^b   Casulli, F ^a   Ghiggini, M ^c   Peluso, A ^c   Pricolo, G ^a   Prudenzano, A ^a   Stani, L ^a  

^a SS Annunziata Hospital   (Italy)

^b Department of Internal Medicine   (Italy)

^c Nord Hospital   (Italy)

^d c/o Osp Nord Div di Ematologia ^*  (Italy)

Author keywords

Elderly; Myeloablative therapy; PBSC

Indexed keywords

ANTINEOPLASTIC AGENT; BUSULFAN; CD34 ANTIGEN; CYCLOPHOSPHAMIDE; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN;

ACUTE LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD DISEASE; CANCER; CARDIOTOXICITY; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONGESTIVE HEART FAILURE; DISEASE COURSE; FEASIBILITY STUDY; FEMALE; FEVER; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUMAN CELL; LIVER TOXICITY; LUNG CANCER; LYMPHOMA; MALE; MUCOSA INFLAMMATION; MYELOMA; NEPHROTOXICITY; PERTHES DISEASE; PNEUMONIA; PRIORITY JOURNAL; SALVAGE THERAPY; SEPSIS; SURVIVAL;

EID: 0033516297     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1701804     Document Type: Article

References (27)

1. Kessinger A, Vose JM, Bierman PJ et al. Peripheral stem cell transplantation in non-Hodgkin's lymphoma patients. J Hematother 1993; 2: 361-362.
2. Gahrton G. Autologous stem-cell transplantation in multiple myeloma. Wien Med Wochenschr 1995; 145: 52-54.
3. Sweetenham JW, Tachipour G, Milligan D et al. High dose therapy and autologous stem cell rescue for patients with Hodgkin's disease in first relapse after chemotherapy: results from the EBMT. Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 1997; 20: 745-752.
4. Gianni AM, Bregni M, Siena S et al. High dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. New Engl J Med 1997; 336: 1290-1297.
5. Martin C, Torres A, Leon A et al. Autologous peripheral stem cell transplantation (PBSCT) mobilized with G-CSF in AML in first complete remission. Role of intensification therapy in outcome. Bone Marrow Transplant 1998; 21: 375-382.
6. Sweetenham JW, Pearce R, Philip T et al. High-dose therapy and autologous bone marrow transplantation for intermediate-and high-grade non-Hodgkin's lymphoma in patients aged 55 years and over: results from the European Group for Bone Marrow Transplantation. The EBMT Lymphoma Working Party. Bone Marrow Transplant 1994; 14: 981-987.
7. Dumontet C, Ketterer N, Espinouse D et al. Reduced progression-free survival in elderly patients receiving intensification with autologous peripheral blood stem cell reinfusion for multiple myeloma. Bone Marrow Transplant 1998; 21: 1037-1041.
8. Miller CB, Piantadosi S, Vogelsang GB et al. Impact of age on outcome of patients with cancer undergoing autologous bone marrow transplant. J Clin Oncol 1996; 14: 1327-1332.
9. Stamatoullas A, Fruchart C, Khalfallah S et al. Peripheral blood stem cell transplantation for relapsed or refractory aggressive lymphoma in patients over 60 years of age. Bone Marrow Transplant 1997; 19: 31-35.
10. Moreau P, Milpied N, Voillat L et al. Peripheral blood stem cell transplantation as front-line therapy in patients aged 61 to 65 years: a pilot study. Bone Marrow Transplant 1998; 21: 1193-1196.
11. Ferrara F, Mirto S, Zagonel V, Pinto A. Acute myeloid leukemia in the elderly: a critical review of therapeutic approaches and appraisal of results of therapy. Leuk Lymphoma 1998; 29: 375-382.
12. Zinzani PL, Pavone E, Storti S et al. Randomized trial with or without granulocyte colony-stimulating factor as adjunct to induction VNCOP-B treatment of elderly high-grade non-Hodgkin's lymphoma. Blood 1997; 89: 3974-3979.
13. Magrath IT. Non-Hodgkin's lymphomas: epidemiology and treatment. Ann NY Acad Sci 1997; 824: 91-106.
14. Newton R, Ferlay J, Beral V, Devesa SS. The epidemiology of non-Hodgkin's lymphoma: comparison of nodal and extranodal sites. Int J Cancer 1997; 72: 923-930.
15. Gomez H, Mas L, Casanova L et al. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity. J Clin Oncol 1998; 16: 2352-2358.
16. Abrahamson GM, Bird JM, Newland AC et al. A randomized study of VAD with either concurrent or maintenance interferon in patients with newly diagnosed multiple myeloma. Br J Haematol 1996; 94: 659-664.
17. Montillo M, Mirto S, Petti MC et al. Fludarabine, cytarabine, and G-CSF (FLAG) for the treatment of poor risk acute myeloid leukemia. Am J Hematol 1998; 58: 105-109.
18. GIMEMA Group. GIMEMA ALL 0183: a multicentric study on adult acute lymphoblastic leukaemia in Italy. GIMEMA Cooperative Group. Br J Haematol 1989; 71: 377-386.
19. Craig JI, Anthony RS, Stewart A et al. Peripheral blood stem cell mobilization using high-dose cyclophosphamide and G-CSF in pretreated patients with lymphoma. Br J Haematol 1993; 85: 210-212.
20. Mills W, Chopra R, McMillan A et al. BEAM chemotherapy and autologous bone marrow transplantation for patients with relapsed or refractory non-Hodgkin's lymphoma. J Clin Oncol 1995; 13: 588-595.
21. Alegre A, Diaz-Mediavilla J, San-Miguel J et al. Autologous peripheral blood stem cell transplantation for multiple myeloma: a report of 259 cases from the Spanish Registry. Spanish Registry for Transplant in MM (Grupo Espanol de Transplante Hematopoyetico-GETH) and PETHEMA. Bone Marrow Transplant 1998; 21: 133-140.
22. Horowitz MM, Rowlings PA. An update from the international Bone Marrow Transplant Registry and the Autologous Blood and Marrow Transplant Registry on current activity in hematopoietic stem cell transplantation. Curr Opin Hematol 1997; 4: 395-400.
23. Messori A, Bonistalli L, Costantini M, Alterini R. Cost-effectiveness of autologous bone marrow transplantation in patients with relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 1997; 19: 275-281.
24. Mazza P, Secondo E, Palazzo G et al. Cost of salvage high-dose therapy and blood stem cell transplantation (PBSC) for resistant-relapsed malignant lymphomas in a southern Italian hospital. Haematologica 1999; 84: 142-149.
25. Philip T, Guglielmi C, Hagenbeek A et al. Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy sensitive non-Hodgkin's lymphoma. New Engl J Med 1995; 333: 1540-1545.
26. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. New Engl J Med 1996; 335: 91-97.
27. Sucu S, Mandelli F, De Witte T et al. Results of post-consolidation treatment for patients less than 50 years of age with AML in first complete remission in the AML 10 study of the Leukemia Cooperative Study Group and the EORTC-GIMEMA. Bone Marrow Transplant 1998; 21 (Suppl. 1): S12.